BridgeBio Pharma (NASDAQ:BBIO) Chairman Charles J. Homcy sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $36.00, for a total value of $720,000.00. Following the completion of the sale, the chairman now directly owns 1,342,291 shares in the company, valued at approximately $48,322,476. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Charles J. Homcy also recently made the following trade(s):
- On Tuesday, January 14th, Charles J. Homcy sold 10,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $35.00, for a total value of $350,000.00.
Shares of BridgeBio Pharma stock opened at $34.05 on Friday. The company has a quick ratio of 14.00, a current ratio of 14.00 and a debt-to-equity ratio of 0.14. BridgeBio Pharma has a 12 month low of $17.61 and a 12 month high of $48.36. The business has a fifty day simple moving average of $34.71 and a 200 day simple moving average of $29.20.
BBIO has been the subject of several analyst reports. Raymond James raised their target price on BridgeBio Pharma from to in a research report on Tuesday, January 7th. Zacks Investment Research upgraded BridgeBio Pharma from a “sell” rating to a “hold” rating in a research report on Monday, January 6th. Piper Jaffray Companies dropped coverage on BridgeBio Pharma in a research note on Friday, October 18th. Finally, UBS Group began coverage on BridgeBio Pharma in a research note on Tuesday, December 3rd. They issued a “reduce” rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. BridgeBio Pharma presently has a consensus rating of “Buy” and an average target price of $40.63.
BridgeBio Pharma Company Profile
BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.
Featured Article: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.